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To the Editor: In reference to the recent articles regarding
Kt/V,1,2 a hemodialysis Kt/V41.0 implies there is complete
removal of urea from a volume of body water which exceeds
the total volume of water in the body, an impossibility,
occurring because it measures dialyzer, not patient, clearance.
Kt/V for peritoneal dialysis is based on the actual amount of
urea removed, explaining the discrepancy between the
recommended weekly Kt/V in hemodialysis patients, 3.6
(3 1.2)–4.2 (3 1.4), compared to the weekly Kt/V in
peritoneal dialysis patients, 1.7–2.0.3 If the urea reduction ratio
(URR) represents the actual amount of urea removed per
hemodialysis treatment, with three sessions in a week, each
with a urea reduction ratio of 0.65–0.70, would remove about
1.95–2.1 times the total body urea content, nearly identical to
the recommended weekly Kt/V for peritoneal dialysis.
Kt/V is a flawed concept as used in hemodialysis and
results in a fictitious and questionably meaningful number,
but does have a useful role in peritoneal dialysis. URR more
accurately reflects solute removal.
1. Spalding EM, Chandna SM, Davenport A et al. Kt/V underestimates the
hemodialysis dose in women and small men. Kidney Int 2008; 74: 348–355.
2. Lowrie EG. Prescribing and monitoring hemodialysis dose. Kidney Int 2008;
74: 262–264.
3. Hemodialysis Adequacy 2006 Work Group. Clinical practice guidelines for
hemodialysis adequacy, update 2006. Am J Kidney Dis 2006; 48(Suppl 1):
S2–S175.
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I agree completely with Dr Jenkins’ impression that Kt/V is
clinically illogical for reasons explained in the Commentary he
cites.1 In addition, Eloot et al. have recently found better urea
removal when patients are treated for a longer time (t) despite
comparable Kt/V.2 Those data illustrate one more reason why
K, t, and V should not be combined as a single ratio; we have
one more fact indicating the clinical ‘illogic of Kt/V’.
I respectfully disagree with his reason, however, because
Kt/V41.0 does not indicate complete urea removal. The
fact is revealed by his claim that urea reduction ratio
(URR) reflects solute removal better than Kt/V. Urea
kinetic equations prove that URR and Kt/V are tightly
linked as the following illustrates:
(1) BUN at end of dialysis (Ct)¼ predialysis concentration
(CO) eKt/V, so
(2) Ct /CO¼ eKt/V, and
(3) URR¼ 100 (COCt)/CO¼ 100 (1Ct/CO), so
(4) URR¼ 100 (1eKt/V).
Therefore, URR and Kt/V can be calculated from each
other and one cannot reasonably argue in the same breath
that URR is appropriate but Kt/V is not.
This example shows that Kt/V¼ 0.5-URR¼ 39%,
Kt/V¼ 1.0-URR¼ 63%, and Kt/V¼ 1.5-URR¼ 78%.
Note also that URR¼ 99%’Kt/V¼ 4.6, URR¼ 99.9%’Kt/
V¼ 6.9, and URR ¼ 99.99%’Kt/V¼ 9.2. So, although Kt/V
is not appropriate for evaluating clinical outcome,1 it does
reflect that URR and Kt/V41.0 is perfectly logical.
The confusion probably evolved from misleading
statements suggesting Kt/V reflects a ‘fractional clearance’
of urea. For example, we find,
‘‘To normalize for differences in the size and habitus of
patients, a dose of hemodialysis (prescribed or delivered) is
best described as the fractional clearance of urea as a
function of its distribution volume (Kt/V)’’.3 (Emphasis
added)
Such unclear statements likely suggested to many that
when, for example, Kt/V¼ 48 l/40 l¼ 1.2 the ‘fractional
clearance’ would be 120%, so those 40 l should be
completely ‘cleared’. Unfortunately, the concept is incorrect
as I hope I have shown.
1. Lowrie EG. Prescribing and monitoring hemodialysis dose. Kidney Int 2008;
74: 262–264.
2. Eloot S, Van Biesen W, Dhondt A et al. Impact of hemodialysis duration on
the removal of uremic retention solutes. Kidney Int 2008; 73: 765–770.
3. NKF K/DOQI Guidelines 2000, Guideline #2: Method of Measurement of
Delivered Dose of Hemodialysis (Evidence) http://www.kidney.org/
PROFESSIONALS/kdoqi/guidelines_updates/doqi_uptoc.html.
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Our paper1 was not intended to praise the Kt/V concept of
dialysis adequacy but to provide some constructive
criticism. Jenkins raises some theoretical issues that relate
to the validity of the whole Kt/V concept in the
hemodialysis setting, whereas our paper drew attention
to potential problems with the concept of using V, an
estimate of total body water, to normalize estimated
urea clearance. We provided some support for the use of
a normalizing factor, which better reflects metabolic
activity.
There are a number of issues. First, whether any
measure of urea removal is sufficient to judge dialysis
http://www.kidney-international.org l e t t e r t o t h e e d i t o r
& 2009 International Society of Nephrology
Kidney International (2009) 75, 337–340 337
adequacy; second, if a measure of urea removal were to be
used, whether a simple urea reduction ratio is acceptable
or whether a measure that incorporates a normalizing
factor is necessary; and finally – whether the widespread
use of V as this normalizing factor is valid. Jenkins’
criticisms relate to the second point whereas our paper
addressed the third.
Focusing solely on normalized urea clearance presents a
flawed view of dialysis adequacy. There are many other
facets. Middle molecule removal is important. Reanalysis
of data from the HEMO study has demonstrated that
retention of b2 microglobulin was associated with in-
creased mortality.2 In addition to solute clearances, dialysis
prescription encompasses other goals, including sodium
and water, divalent ion and acid-base homeostasis. Dialysis
hypotension is more likely to occur when dialysis session
time is shortened, because of increased ultrafiltration rates,
and failure to achieve adequate sodium removal with
increased interdialytic weight gains.
Although we have criticized the appropriateness of the
use of Kt/V in prescribing hemodialysis, we do believe that
an assessment of the amount of dialysis delivered is vital,
unless very long and/or very frequent dialysis sessions
are employed. Normalized urea clearance, although not
perfect, is a useful marker of adequacy, though we believe
it could be used more astutely. Our paper proposes that the
normalizing factor should reflect metabolic activity, as use
of V may risk under-dialysis in women and small men. We
suggest that this should be borne in mind while we
continue to use Kt/V, and that the adequacy targets should
be adjusted in these two groups.
1. Spalding EM, Chandna SM, Davenport A et al. Kt/V underestimates
the hemodialysis dose in women and small men. Kidney Int 2008; 74:
348–355.
2. Cheung AK, Rocco MV, Yan G et al. Serum beta-2 microglobulin levels
predict mortality in dialysis patients: results of the HEMO study. J Am Soc
Nephrol 2006; 17: 546–555.
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To the Editor: We have read with interest the article by
Hai-Lu Zhao et al.1 on fat redistribution and adipocyte
transformation in uninephrectomized rats. Among numerous
interesting findings, the authors demonstrate increased
ectopic fat deposits in remnant kidneys and other solid
organs of chronic kidney disease animals. The authors
speculate on the possible mechanisms, taking into account
increased lipid production. This hypothesis is strengthened
by demonstrating that expression of HMG-CoA reductase,
the rate-limiting enzyme in cholesterologenesis pathway, is
increased in remnant kidneys.
We would like to confirm these results and highlight the
potential role of sterol regulatory element-binding proteins
(SREBPs) in the above-mentioned disturbances. SREBPs are
nuclear transcription factors that are currently regarded as
the major regulators of both cholesterologenesis and
lipogenesis.
We have shown that both gene expression and protein
abundance of SREBPs are increased in white adipose tissue2
and livers3 of chronic kidney disease rats. Moreover, increase
in SREBP expression has been demonstrated in kidneys of
diabetic mice4 and in experimental age-related nephropathy,5
where it has been clearly linked to lipid deposition in
glomeruli, and consequently to mesangial expansion, glo-
merulosclerosis, and proteinuria.
These results complement the findings demonstrated by
Zhao et al. as they bring us closer to elucidating the issue of
altered lipid metabolism in the course of chronic kidney
disease.3
1. Zhao HL, Sui Y, Guan J et al. Fat redistribution and adipocyte
transformation in uninephrectomized rats. Kidney Int 2008; 74:
467–477.
2. Korczynska J, Stelmanska E, Nogalska A et al. Upregulation of lipogenic
enzymes genes expression in white adipose tissue of rats with chronic
renal failure is associated with higher level of sterol regulatory element
binding protein-1. Metabolism 2004; 53: 1060–1065.
3. Szolkiewicz M, Chmielewski M, Nogalska A et al. The potential role of sterol
regulatory element binding protein transcription factors in renal injury.
J Ren Nutr 2007; 17: 62–65.
4. Sun L, Halaihel N, Zhang W et al. Role of sterol regulatory element-binding
protein 1 in regulation of renal lipid metabolism and glomerulosclerosis in
diabetes mellitus. J Biol Chem 2002; 277: 18919–18927.
5. Jiang T, Liebman SE, Lucia MS et al. Role of altered renal lipid metabolism
and the sterol regulatory element binding proteins in the pathogenesis of
age-related renal disease. Kidney Int 2005; 68: 2608–2620.
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We thank Chmielewski et al. for drawing attention to the
potential role of sterol regulatory element-binding
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